JPH10147529A5 - - Google Patents

Info

Publication number
JPH10147529A5
JPH10147529A5 JP1997298654A JP29865497A JPH10147529A5 JP H10147529 A5 JPH10147529 A5 JP H10147529A5 JP 1997298654 A JP1997298654 A JP 1997298654A JP 29865497 A JP29865497 A JP 29865497A JP H10147529 A5 JPH10147529 A5 JP H10147529A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
effective amount
period
compound
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997298654A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10147529A (ja
Filing date
Publication date
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed filed Critical
Publication of JPH10147529A publication Critical patent/JPH10147529A/ja
Publication of JPH10147529A5 publication Critical patent/JPH10147529A5/ja
Pending legal-status Critical Current

Links

JP9298654A 1996-10-30 1997-10-30 乳癌を予防する方法 Pending JPH10147529A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
US60/029850 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10
US60/040260 1997-03-10
US9624800 1997-03-10

Publications (2)

Publication Number Publication Date
JPH10147529A JPH10147529A (ja) 1998-06-02
JPH10147529A5 true JPH10147529A5 (2) 2005-07-07

Family

ID=27268608

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9298654A Pending JPH10147529A (ja) 1996-10-30 1997-10-30 乳癌を予防する方法
JP9298682A Withdrawn JPH10147530A (ja) 1996-10-30 1997-10-30 乳癌の予防に関する改善

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP9298682A Withdrawn JPH10147530A (ja) 1996-10-30 1997-10-30 乳癌の予防に関する改善

Country Status (43)

Country Link
US (2) US6303634B1 (2)
EP (3) EP1369115B1 (2)
JP (2) JPH10147529A (2)
CN (2) CN1182591A (2)
AP (1) AP971A (2)
AR (2) AR013864A1 (2)
AT (2) ATE239475T1 (2)
AU (3) AU5005697A (2)
BE (2) BE1011381A5 (2)
BG (1) BG63841B1 (2)
BR (1) BR9712703A (2)
CA (2) CA2219377A1 (2)
CH (2) CH691847A5 (2)
CZ (2) CZ341297A3 (2)
DE (2) DE69736644T2 (2)
DK (2) DK1369115T3 (2)
EA (2) EA002054B1 (2)
EE (1) EE03663B1 (2)
ES (4) ES2135343A1 (2)
FR (2) FR2756490B1 (2)
GB (3) GB2318733A (2)
GE (1) GEP20032910B (2)
GR (2) GR970100409A (2)
HU (2) HUP9701778A3 (2)
IE (2) IE970773A1 (2)
IL (2) IL122026A0 (2)
IS (1) IS5035A (2)
IT (2) IT1298470B1 (2)
LU (2) LU90158B1 (2)
LV (1) LV12353B (2)
MY (1) MY121623A (2)
NL (2) NL1007386C2 (2)
NO (2) NO974973D0 (2)
NZ (1) NZ329042A (2)
PT (2) PT1369115E (2)
RO (1) RO120813B1 (2)
SG (2) SG83672A1 (2)
SI (3) SI0839532T1 (2)
SK (1) SK287047B6 (2)
TR (1) TR199900951T2 (2)
UA (1) UA46762C2 (2)
WO (2) WO1998018449A1 (2)
YU (1) YU42397A (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
FI982733A7 (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
ES2259376T3 (es) 2001-05-22 2006-10-01 Eli Lilly And Company 1,2,3,4-tetrahidroquinolinas 2-sustituidas y sus derivados, composiciones y procedimientos.
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
MX2023013107A (es) * 2023-11-06 2025-06-02 Centro De Investig Y De Estudios Avanzados Del I P N Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
KR950010891A (ko) * 1993-10-15 1995-05-15 피터 지. 스트링거 내성 종양을 치료하는 방법
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
UA57596C2 (uk) * 1996-03-26 2003-06-16 Елі Ліллі Енд Компані Похідне бензотіофену, фармацевтична лікарська форма, фармацевтична композиція, спосіб лікування остеопорозу та спосіб зниження рівнів ліпідів

Similar Documents

Publication Publication Date Title
JPH10147529A5 (2)
RU96119781A (ru) Применение 2-фенил-3-ароилбензотиофенов для снижения уровня холестерина в сыворотке, фармацевтическая композиция
EP0284612B1 (en) Treatment of bone loss
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
RU2003119460A (ru) Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с
DK0503440T3 (da) Sumatriptanholdige lægemidler
CA2440111A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
PT1227806E (pt) Formulacao farmaceutica contendo tolterodina e sua utilizacao
JP2002529490A (ja) 歯牙吸収性病変の阻害方法
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
JP2005515966A5 (2)
JP2009102342A5 (2)
JPH11193282A5 (2)
JP2001526218A5 (2)
RU98115774A (ru) Новые производные 19-нор-прегнена
JP2007520452A5 (2)
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
RU2003105159A (ru) Способ лечения климактерических расстройств у женщин во время или после менопаузы
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
JP2000159790A5 (2)
JP2002522501A5 (2)
RU2004131214A (ru) Способы лечения когнитивных расстройств
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
JP2002540148A5 (2)